| Bioactivity | SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (MPro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM[1]. |
| Target | MPro/CatL |
| Invitro | SARS-CoV-2 Mpro-IN-4 (SM141) blocks SARS-CoV2 replication in A549-hACE2 cells with IC50 value of 8.2 nM[1].SARS-CoV-2 Mpro-IN-4 (50 μM, 24 h) does not cause any notable cytotoxicity in A549-hACE2 cells[1].SARS-CoV-2 Mpro-IN-4 inhibits OC-43 virus mRNA expression A549 cells[1].SARS-CoV-2 Mpro-IN-4 inhibits SARS-CoV2 infection by inhibiting both MPro and CatL[1]. |
| In Vivo | SARS-CoV-2 Mpro-IN-4 (SM141) (10 mg/kg for i.n. or 25 mg/kg for i.p.) protects K18-ACE2 mice from SARS-CoV2-induced weight loss and lethality[1].SARS-CoV-2 Mpro-IN-4 (3 mg/kg, i.v.) shows a short half-life of 0.8 h and high clearance of 72 mL/min/kg in in male C57Bl/6 mice[1].SARS-CoV-2 Mpro-IN-4 (10 mg/kg, p.o.) shows oral bioavailability of 5%[1]. Animal Model: |
| Name | SARS-CoV-2 Mpro-IN-4 |
| Formula | C30H38N4O5 |
| Molar Mass | 534.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mondal S, et al. Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2. J Am Chem Soc. 2022 Nov 23;144(46):21035-21045. |